KR101580348B1 - 안정한 철 올리고당 화합물 - Google Patents

안정한 철 올리고당 화합물 Download PDF

Info

Publication number
KR101580348B1
KR101580348B1 KR1020117025035A KR20117025035A KR101580348B1 KR 101580348 B1 KR101580348 B1 KR 101580348B1 KR 1020117025035 A KR1020117025035 A KR 1020117025035A KR 20117025035 A KR20117025035 A KR 20117025035A KR 101580348 B1 KR101580348 B1 KR 101580348B1
Authority
KR
South Korea
Prior art keywords
dextran
weight
molecular weight
iron
hydrogenated
Prior art date
Application number
KR1020117025035A
Other languages
English (en)
Korean (ko)
Other versions
KR20120016063A (ko
Inventor
한스 안드리아센
Original Assignee
파르마코스모스 홀딩 에이/에스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41350678&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101580348(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 파르마코스모스 홀딩 에이/에스 filed Critical 파르마코스모스 홀딩 에이/에스
Publication of KR20120016063A publication Critical patent/KR20120016063A/ko
Application granted granted Critical
Publication of KR101580348B1 publication Critical patent/KR101580348B1/ko

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0021—Dextran, i.e. (alpha-1,4)-D-glucan; Derivatives thereof, e.g. Sephadex, i.e. crosslinked dextran
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/721—Dextrans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C07H3/06—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Polymers & Plastics (AREA)
  • Materials Engineering (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020117025035A 2009-03-25 2009-03-25 안정한 철 올리고당 화합물 KR101580348B1 (ko)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/DK2009/050069 WO2010108493A1 (en) 2009-03-25 2009-03-25 A stable iron oligosaccharide compound

Publications (2)

Publication Number Publication Date
KR20120016063A KR20120016063A (ko) 2012-02-22
KR101580348B1 true KR101580348B1 (ko) 2016-01-04

Family

ID=41350678

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020117025035A KR101580348B1 (ko) 2009-03-25 2009-03-25 안정한 철 올리고당 화합물

Country Status (26)

Country Link
US (7) US8815301B2 (es)
EP (3) EP3156075B1 (es)
JP (1) JP5426010B2 (es)
KR (1) KR101580348B1 (es)
CN (3) CN108752395A (es)
AU (1) AU2009342799B2 (es)
BR (1) BRPI0924653B8 (es)
CA (1) CA2756580A1 (es)
CY (2) CY1118725T1 (es)
DK (2) DK2411053T3 (es)
EA (1) EA023917B1 (es)
ES (2) ES2840074T3 (es)
HK (1) HK1164138A1 (es)
HR (2) HRP20170230T1 (es)
HU (2) HUE052617T2 (es)
LT (2) LT3156075T (es)
MX (1) MX2011009936A (es)
NZ (1) NZ595597A (es)
PH (1) PH12015500891B1 (es)
PL (2) PL3156075T3 (es)
PT (2) PT2411053T (es)
RS (2) RS55700B1 (es)
SI (2) SI3156075T1 (es)
UA (1) UA103373C2 (es)
WO (1) WO2010108493A1 (es)
ZA (1) ZA201107431B (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11912735B2 (en) 2017-08-29 2024-02-27 Chr Hansen Hmo Gmbh Process for purifying sialylated oligosaccharides

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140117678A (ko) 2006-01-06 2014-10-07 루이트폴드 파머수티컬스, 인코퍼레이티드 철을 투여하기 위한 방법 및 조성물
EP3156075B1 (en) 2009-03-25 2020-10-14 Pharmacosmos Holding A/S An oligosaccharide and a process for preparation thereof
CN103626807B (zh) * 2013-11-20 2017-07-07 青岛国风药业股份有限公司 一种多糖铁复合物的制备方法及其质量检测方法
CZ2014451A3 (cs) * 2014-06-30 2016-01-13 Contipro Pharma A.S. Protinádorová kompozice na bázi kyseliny hyaluronové a anorganických nanočástic, způsob její přípravy a použití
BR112017008709A2 (pt) * 2014-10-27 2017-12-26 Pharmacosmos Holding As tratamento ou prevenção da anemia em mamíferos não-humanos grávidos
CN116999459A (zh) * 2015-06-22 2023-11-07 法码科思莫斯控股有限公司 用于治疗胎儿或婴儿铁缺乏的铁碳水化合物复合物
CA2932075C (en) * 2015-09-01 2020-11-17 Particle Dynamics International, Llc Iron-polysaccharide complexes and methods for the preparation thereof
US10258647B2 (en) 2015-09-01 2019-04-16 Particle Dynamics International, Llc Iron-polysaccharide complexes and methods for the preparation thereof
CN105908611A (zh) * 2016-06-12 2016-08-31 天津康远工程机械有限公司 具有清洗功能的自动找平双层预应力烫平板
EP3681539A1 (en) * 2017-09-11 2020-07-22 Pharmacosmos Holding A/S Iron complex compounds for therapeutic use
CN109646454A (zh) * 2018-12-29 2019-04-19 博瑞生物医药（苏州）股份有限公司 异麦芽糖酐铁1000的制备方法
GB2595135B (en) 2019-01-10 2022-10-26 Pharmacosmos Holding As Treating iron deficiency in subjects at risk of cardiovascular adverse events and iron for the management of atrial fibrillation
CN114286682A (zh) 2019-02-09 2022-04-05 法码科思莫斯控股有限公司 治疗具有心血管不良事件风险的个体的铁缺乏以及用于治疗心房颤动的铁
US11447513B2 (en) * 2020-02-12 2022-09-20 Rk Pharma Inc. Purification process of ferric carboxymaltose
BR112024002150A2 (pt) 2021-08-03 2024-04-30 Pharmacosmos Holding As Compostos de complexo de ferro para uso subcutâneo na terapia de deficiência de ferro em animais de companhia
WO2024069644A1 (en) * 2022-09-30 2024-04-04 West Bengal Chemical Industries Limited A pharmaceutically acceptable ferric carboxymaltose and preparation thereof
CN116672360B (zh) * 2023-06-30 2024-05-14 重庆汉佩生物科技有限公司 一种妥曲珠利与葡庚糖酐铁的组合物
CN116726045B (zh) * 2023-06-30 2024-03-19 重庆汉佩生物科技有限公司 一种氟雷拉纳组合物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000030657A1 (en) 1998-11-20 2000-06-02 Pharmacosmos Holding A/S A process for producing an iron-dextran compound

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA623412A (en) 1961-07-04 Muller Arthur Iron polyisomaltose complexes for therapeutical application
CA623411A (en) 1961-07-04 Muller Arthur Process for the manufacture of iron-polyisomaltose complex for therapeutical purposes
US2807610A (en) * 1952-02-15 1957-09-24 Baker Chem Co J T Hydrogenated dextran
US3100202A (en) 1960-06-17 1963-08-06 Muller Arthur Process for preparing an iron hydroxide polyisomaltose complex and the resulting product
US3076798A (en) 1961-02-23 1963-02-05 Hausmann Lab Ltd Process for preparing a ferric hydroxide polymaltose complex
DE1293144B (de) 1964-11-04 1969-04-24 Hausmann Ag Labor Verfahren zur Herstellung von Komplexverbindungen des Eisens mit Sorbit, Gluconsaeure und einem Oligosaccharid
US3639588A (en) 1966-10-22 1972-02-01 Fisons Pharmaceuticals Ltd Pharmaceutical compositions containing ferric hydroxide complexed with dextran or dextrin heptonic acids
GB1594697A (en) * 1977-04-19 1981-08-05 Pharmacia Ab Oligosaccharide compositions for parenteral use
DE3026868C2 (de) 1980-07-16 1986-03-13 Laboratorien Hausmann AG, St. Gallen Verfahren zur Herstellung von Eisen(III)hydroxid-Dextran-Komplexen und sie enthaltende pharmazeutische sterile wäßrige Lösung
US4518581A (en) * 1981-11-02 1985-05-21 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Imparting low- or anti-cariogenic property to orally-usable products
DE3422249A1 (de) 1984-06-15 1985-12-19 Pfeifer & Langen, 5000 Köln Wasserloesliches eisendextran und verfahren zu seiner herstellung
US5624668A (en) 1995-09-29 1997-04-29 Luitpold Pharmaceuticals, Inc. Iron dextran formulations
US6219440B1 (en) 1997-01-17 2001-04-17 The University Of Connecticut Method and apparatus for modeling cellular structure and function
DK172860B1 (da) 1998-03-25 1999-08-16 Pharmacosmos Holding As Jerndextranforbindelse til anvendelse som komponent i et terapeutisk middel til forebyggelse af eller behandling af jernman
EP1169062B1 (en) 1999-04-09 2009-10-21 AMAG Pharmaceuticals, Inc. Heat stable coated colloidal iron oxides
US7871597B2 (en) 1999-04-09 2011-01-18 Amag Pharmaceuticals, Inc. Polyol and polyether iron oxide complexes as pharmacological and/or MRI contrast agents
KR20020096284A (ko) * 2001-06-19 2002-12-31 현대자동차주식회사 자동차의 연료 누유 진단장치
BR0308773A (pt) * 2002-04-09 2005-02-09 Pharmacosmos Holding As Compostos de dextrina de ferro para tratamento de anemia por deficiência de ferro
DE10249552A1 (de) 2002-10-23 2004-05-13 Vifor (International) Ag Wasserlösliche Eisen-Kohlenhydrat-Komplexe, deren Herstellung und diese enthaltende Arzneimittel
US20060116349A1 (en) 2003-03-14 2006-06-01 Luitpold Pharmaceuticals, Inc. Methods and compositions for administration of iron for the treatment of restless leg syndrome
US6960571B2 (en) 2003-03-14 2005-11-01 Luitpold Pharmaceuticals, Inc. Methods and compositions for administration of iron for the treatment of restless leg syndrome
US7964568B2 (en) * 2003-05-30 2011-06-21 Chromaceutical Advanced Technologies, Inc. Synthesis of high molecular weight iron-saccharidic complexes
UA88347C2 (ru) * 2005-02-09 2009-10-12 Вифор (Интернешенл) Аг Применение комплексных соединений железа (iii) с углеводами или их производными в изготовлении медикамента для улучшения иммунной защиты и/или мозговой функции у пациентов без анемии
ITMO20050056A1 (it) 2005-03-15 2006-09-16 Biofer Spa Processo per la preparazione di complessi del ferro trivalente con zuccheri mono-, di- e polisaccaridi.
CN100528237C (zh) * 2005-04-26 2009-08-19 重庆医药工业研究院有限责任公司 多核的氢氧化铁-糖复合物的制备方法
EP1757299A1 (de) 2005-08-25 2007-02-28 Vifor (International) Ag Eisen(III)-Komplexverbindungen zur Behandlung von Eisenmangel-Zuständen bei Patienten mit chronisch-entzündlicher Darmerkrankung
KR20140117678A (ko) 2006-01-06 2014-10-07 루이트폴드 파머수티컬스, 인코퍼레이티드 철을 투여하기 위한 방법 및 조성물
EP1997833A1 (de) 2007-05-29 2008-12-03 Vifor (International) Ag Wasserlösliche Eisen-Kohlenhydratderivat-Komplexe, deren Herstellung und diese enthaltende Arzneimittel
EP3156075B1 (en) 2009-03-25 2020-10-14 Pharmacosmos Holding A/S An oligosaccharide and a process for preparation thereof
EP2877848A4 (en) 2012-07-27 2016-03-23 Intrinsic Life Sciences Llc METHOD FOR TREATING FERMENTED ANEMIA
WO2014071194A2 (en) 2012-11-01 2014-05-08 Katz Robert S Methods for treating fibromyalgia
EP3925443A1 (en) 2012-11-30 2021-12-22 Pharmacosmos Holding A/S Cryoprotecting agent, cryoprotecting and cryopreserved compositions, uses thereof, and methods of cryopreservation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000030657A1 (en) 1998-11-20 2000-06-02 Pharmacosmos Holding A/S A process for producing an iron-dextran compound
US20030083310A1 (en) 1998-11-20 2003-05-01 Pharmacosmos Holding A/S Process for producing an iron-dextran compound, iron-dextran compound produced according to said process, pharmaceutical composition for prophylaxis or treatment of iron-deficiency and use of said compound for the preparation of a parenterally administrable pharmaceutical composition

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11912735B2 (en) 2017-08-29 2024-02-27 Chr Hansen Hmo Gmbh Process for purifying sialylated oligosaccharides

Also Published As

Publication number Publication date
EP2411053B1 (en) 2016-11-30
US20140303364A1 (en) 2014-10-09
KR20120016063A (ko) 2012-02-22
US9439969B2 (en) 2016-09-13
CN108752395A (zh) 2018-11-06
MX2011009936A (es) 2011-10-06
BRPI0924653A2 (pt) 2016-01-26
EA201190214A1 (ru) 2012-04-30
PH12015500891A1 (en) 2016-11-14
LT2411053T (lt) 2017-04-10
US10865255B2 (en) 2020-12-15
HRP20201903T1 (hr) 2021-01-22
CY1118725T1 (el) 2017-07-12
RS55700B1 (sr) 2017-07-31
BRPI0924653B8 (pt) 2021-05-25
PL3156075T3 (pl) 2021-04-19
WO2010108493A1 (en) 2010-09-30
DK3156075T3 (da) 2020-11-30
PT2411053T (pt) 2017-02-15
US20190135947A1 (en) 2019-05-09
EP3156075A1 (en) 2017-04-19
ZA201107431B (en) 2012-07-25
DK2411053T3 (en) 2017-02-20
US20140364598A1 (en) 2014-12-11
PH12015500891B1 (en) 2016-11-14
PT3156075T (pt) 2021-01-05
EP2411053A1 (en) 2012-02-01
CN109700828A (zh) 2019-05-03
CN102361651A (zh) 2012-02-22
RS61104B1 (sr) 2020-12-31
ES2617658T3 (es) 2017-06-19
LT3156075T (lt) 2021-01-11
US20120010166A1 (en) 2012-01-12
US10414831B2 (en) 2019-09-17
JP2012521369A (ja) 2012-09-13
HK1164138A1 (zh) 2012-09-21
SI2411053T1 (sl) 2017-04-26
EP3821910A1 (en) 2021-05-19
AU2009342799B2 (en) 2014-12-18
JP5426010B2 (ja) 2014-02-26
EA023917B1 (ru) 2016-07-29
ES2840074T3 (es) 2021-07-06
HRP20170230T1 (hr) 2017-04-07
AU2009342799A1 (en) 2011-11-03
EP3156075B1 (en) 2020-10-14
HUE030866T2 (en) 2017-06-28
US8815301B2 (en) 2014-08-26
BRPI0924653B1 (pt) 2019-10-08
CA2756580A1 (en) 2010-09-30
SI3156075T1 (sl) 2021-03-31
HUE052617T2 (hu) 2021-05-28
UA103373C2 (ru) 2013-10-10
PL2411053T3 (pl) 2017-06-30
CY1123651T1 (el) 2022-03-24
US11851504B2 (en) 2023-12-26
US20160333118A1 (en) 2016-11-17
NZ595597A (en) 2013-05-31
US20210108004A1 (en) 2021-04-15
US20210130505A1 (en) 2021-05-06

Similar Documents

Publication Publication Date Title
KR101580348B1 (ko) 안정한 철 올리고당 화합물
AU740432B2 (en) An iron-dextran compound for use as a component in a therapeutical composition for prophylaxis or treatment of iron-deficiency, a process for producing said iron-dextran compound and use of said compound for the preparation of a parenterally administrable therapeutic composition
EP1492821B1 (en) Iron dextrin compounds for the treatment of iron deficiency anaemia

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20181129

Year of fee payment: 4